Top Social Impact Companies in NYC, NY (270)

Investor Backing & Capital Strength: Capital momentum includes a $100M Series D in July 2024 at a higher valuation, signaling strong support for continued expansion. The raise is characterized as a notable step-up in a challenging health-tech funding climate.

Market Expansion: Geographic and payer reach are widening with nationwide availability and announced rollouts into Medicare Advantage by late 2024 and Medicaid in 2025. Broader plan connectivity and integrated primary care referral pathways indicate growth beyond the original commercial focus.

Strong Revenue Growth: Revenue is described as more than doubling over the prior 12 months alongside rising appointment volume and a rapidly expanding provider network. Milestones such as 1,000,000+ patients connected and millions of care hours delivered reinforce throughput growth.

Strong Revenue Growth: Direct revenue is advancing at a clear double‑digit pace into 2026, with sustained momentum following strong full‑year gains in 2025 and management reiterating a path toward roughly $1B in 2027. Results also show growing payers and higher revenue per payer, indicating expansion on both volume and monetization.

Profitability: Operating income and margins have expanded materially alongside revenue, pointing to improving unit economics. Rising contribution and EBITDA metrics indicate the growth is translating into healthier profitability rather than purely top‑line increases.

Market Expansion: The app has expanded across Europe and Latin America, often ranking among top downloaded or grossing charts in new markets. Company disclosures cite strong MAU gains in targeted European markets and continued international scaling.

Innovation-Driven Growth: Public changelogs and help-center updates show a steady cadence of new releases through mid-2026, including AI meeting reminders, payroll/permissions, and enrollment/billing enhancements. Continuous additions across billing, payroll, enrollment, and messaging suggest a widening product surface that can replace point tools.

Strategic Partnerships: State and agency procurement materials list the platform among approved or competing CCMS vendors, and distribution via channels like Carahsoft’s GSA schedule expands access. Inclusion in statewide initiatives (e.g., Indiana’s program window) typically precedes additional deployments.

Strong Revenue Growth: Company materials and profiles indicate ARR doubled over the past year and is expected to at least double again, aligning with visible adoption signals such as “5,000+ child care programs.” App‑store activity and multi‑site case studies further support momentum in customer acquisition.

Profitability: Adjusted EBITDA remained robust in 2025 (about $270M, ~34% margin) and 2026 guidance was lifted to $240–$250M, indicating healthy margins despite softer top-line trends. Strong quarterly EBITDA and cash generation in 1H 2026 underscore financial durability through the transition.

Diversified Revenue Streams: Pharma Direct and subscriptions are scaling quickly (Pharma Direct +41% in 2025 and +76–82% YoY in 1H 2026; subscriptions +16% in Q1 and +39% in Q2 2026), broadening the mix beyond the legacy coupon business. Management continues to position these segments as key growth drivers that can offset core declines over time.

Product Line Growth: New offerings such as condition‑specific programs (notably weight‑loss/GLP‑1), the GoodRx Companion membership, and initiatives like Employer Direct expand the product footprint. Deeper manufacturer relationships and program integrations (including presence on the federal TrumpRx.gov platform) further extend the solution set.

Investor Backing & Capital Strength: A new $10 million raise in July 2026, described as part of a $30M+ round, alongside recent SEC filings indicates continued capital formation to fund expansion and hiring. Prior institutional backing provides runway to execute growth plans.

Strong Hiring & Retention: The company’s Greenhouse jobs board lists current openings in peer support and outreach roles, signaling active headcount additions rather than a freeze. Continued expansion of these roles would demonstrate that growth plans are being operationalized.

Market Expansion: The company’s site shows operations across Florida, Ohio, Michigan, Virginia, and Washington, evidencing a multi‑state footprint with room to deepen as funding allows. Active recruiting across these states supports ongoing build‑out.

Strong Revenue Growth: Revenue is rising at strong double-digit rates through mid-2026, with additional momentum from growing paying subscribers and ARPU. Upbound also points to continued annual expansion since the January 2025 acquisition.

Diversified Revenue Streams: Segment revenues increased across subscription, transfer-fee, and marketplace lines versus 2025, aided by growth in subscription customers. This mix broadens monetization beyond a single source.

Investor Backing & Capital Strength: Upbound closed an acquisition valued up to $460 million, established a dedicated Brigit segment, and outlined cross-marketing and product-expansion plans. These steps signal resource support and a central role for Brigit inside the parent.

Investor Backing & Capital Strength: Funding is described as a $15.5M Series A in October 2025 led by Costanoa Ventures with participation from Town Hall Ventures and Khosla Ventures, following an earlier 2024 seed. The round is explicitly framed to scale access, hiring, product, and market expansion.

Market Expansion: Go‑to‑market activity is described as expanding beyond New York into states like New Jersey and Ohio with active deployments and continued outreach into 2025–2026. Company materials and public profiles reference multi‑state operations and ongoing hiring to broaden footprint.

Strategic Partnerships: School‑district collaborations are highlighted (e.g., Millville Public Schools) alongside positioning as a school‑centered therapy platform aimed at K‑12 administrators and counselors. The model integrates school‑based referrals with insurer coverage, indicating partnership‑driven growth.

Investor Backing & Capital Strength: The $30M Series B led by Andreessen Horowitz on February 26, 2025, with total funding cited at $50M, supplies meaningful capital to scale. Portfolio inclusion and public “doubling down” commentary from a16z reflect strong external validation.

Market Expansion: Company communications cite 81.8% more clinics and 163% more patients year over year, ~1.5M automated claims, and claims processed in all 50 states. Materials also note growth from an ABA beachhead into PT, ENT/Allergy, and plans for home health, long‑term care, and substance use disorders.

Innovation-Driven Growth: The platform is positioned as AI‑native RCM with reported ~93–95% first‑pass paid rates and one of the largest specialty claims datasets across ABA/SLP/OT/PT. Investor notes and case materials tie these capabilities to improved collections and denial reduction, supporting adoption.

Market Expansion: Public materials indicate the platform footprint has grown to 6,000+ research sites and 25+ sponsors, up from 5,500+ sites cited in late 2025, suggesting continued expansion into 2026. Geographic reach and site participation are portrayed as broadening across dozens of countries.

Strategic Partnerships: Collaborations with large biopharma (e.g., Sanofi, including a 2026 portfolio-level discussion) and integrations with ecosystem vendors like CRIO, RealTime-Devana, and eClinPro signal commercial traction and deeper ecosystem ties. These relationships are positioned to increase marketplace activity and data depth for sponsors and sites.

Innovation-Driven Growth: AI-powered pre-screening and workflow tooling launched in 2025 with ongoing case studies and integrations in 2026, aimed at accelerating enrollment and reducing site burden. The continued rollout of AI features and workflow enhancements suggests rising product maturity and adoption.

Investor Backing & Capital Strength: Late-stage funding rounds—an $88M Series C (2024) and a $150M Series D (2026) led by top-tier firms at a roughly $3B valuation—provide runway for hiring, product development, and broader go-to-market. Feedback suggests this capital base signals strong sponsor conviction and supports continued scaling.

Strong Revenue Growth: Coverage highlights revenue rising from low single-digit millions in 2021 to hundreds of millions by 2024, with subsequent reports indicating around $1B in 2025 alongside surging appointment volumes. Inclusion on the FT/Statista fastest‑growing list reinforces the trajectory.

Market Expansion: Expansion to 125+ insurer partnerships, a nationwide network of roughly 26,000 providers, and new channels with employers and health systems indicate broader distribution. Rising utilization—7M visits in 2025 and 10M lifetime appointments—supports an expanding footprint.

Market Expansion: Geographic coverage is described across numerous U.S. and European cities, with Retrievals support recently extended to Canada—signs of widening reach. Favorable industry conditions around refresh cycles, compliance, and circularity further enable entry into new markets.

Product Line Growth: The company announced Expanded Device Retrievals, adding support for more asset types and flexible packaging options. This broadening of scope indicates active investment in services aligned to modern hybrid and remote workflows.

Strategic Partnerships: Collaborations include programs with Block and the Steve & Marjorie Harvey Foundation and a statewide partnership agreement in California, alongside a roster of recognizable enterprise customers. These relationships point to growing institutional engagement that can open incremental channels.

Market Expansion: Geographic reach is presented as Medicare-covered virtual therapy available across all 50 states, with therapist-by-state listings that signal recent build-out. Statements about operating across many states and serving hundreds to thousands of patients reinforce an expanding footprint.

Strong Hiring & Retention: Active recruiting is visible via an Ashby-powered careers site with roles like a Founding Engineer and multiple remote therapist postings, alongside additional listings on job boards. LinkedIn shows a 51–200 employee range with 140+ listed profiles, consistent with team expansion.

Strategic Partnerships: A collaboration with Advanced Nursing & Home Care (January 2025) extends access through senior-care channels. In-network positioning with Medicare supports referral-driven growth among older adults.

Investor Backing & Capital Strength: Ownership by KIRKBI since 2022 is described as a platform move into digital learning intended to fuel BrainPOP’s growth, with continued emphasis on investment in products and district partnerships. This backing signals long-term capital support and stability for scaling.

Product Line Growth: The company has expanded beyond its core videos with BrainPOP Science and continues to roll out new features and collections such as AI Literacy, assisted grading, and new topics. These additions indicate an active pipeline aimed at deepening classroom use and opening new subject opportunities.

Strong Market Position & Advantage: Materials highlight sizable reach across U.S. schools and districts, with BrainPOP cited as reaching millions of children and being widely embedded in classrooms. Recurring district agreements and broad classroom familiarity suggest durable positioning.

Strong Market Position & Advantage: Independent trade coverage and company materials consistently describe LoanStreet as a leading U.S. platform in loan participations/secondary loan trading, citing a large registered-institution footprint for this niche.

Product Line Growth: The platform has expanded beyond matchmaking into execution, servicing, reporting, and analytics, with newer launches such as CECL reporting and corporate/commercial loan servicing indicating continued suite broadening.

Investor Backing & Capital Strength: A disclosed $25M Series B provides a tangible capital base to fund product investment and go-to-market execution in a regulated B2B workflow category.

Resilient & Sustainable Growth: Recent Form 990 filings indicate total revenue increased from FY2022 through FY2024 to a new high, with annual allograft distribution volumes remaining substantial. As a nonprofit reinvesting in research and operating across multiple clinical segments, growth appears steady and durable.

Strategic Partnerships: Long-term and expanded agreements with Orthofix, Centurion Therapeutics, and Kolosis BIO broaden distribution and add new allograft offerings, while OEM processing relationships (e.g., DBX) deepen channel access. These partnerships support consistent demand and market reach across orthopedics, wound care, and cardiac surgery.

Strong Market Position & Advantage: The organization is frequently described as the world’s largest tissue bank with one of the broadest allograft portfolios, extensive accreditation, and millions of grafts delivered. Consistent inclusion as a major player across relevant market reports reinforces recognized scale and presence despite sizable competitors.